Explore the dramatic shift in South Africa's weight-loss drug market as diabetes treatments like Wegovy, Ozempic, and Mounjaro become household names, raising questions about affordability and access for patients.

South Africa is reviewing 12 generic semaglutide applications after Novo Nordisk’s patent expired, opening a price battle over Ozempic and Africa’s fast-growing GLP-1 market

Novo Nordisk South Africa is set to launch an authorised, more affordable version of semaglutide, aimed at improving access for type 2 diabetes patients.